Results 1 to 10 of about 174,356 (352)
The Ewha Medical Journal, 2021 Over the past decade, substantial advances have been made in the individualization of therapeutic strategies for metastatic colorectal cancer (mCRC).
doaj +1 more source
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol +5 more
core +2 more sources
Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma
Radiology and Oncology, 2018 BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation frequency and their correlation with histological characteristics in Slovenian population have not been ...
Moltara Maja Ebert +6 more
doaj +1 more source
Molecular and genetic diversity in melanoma of eye
Успехи молекулярной онкологии, 2018 Background. Ocular melanoma is the most common cancer of adult eye and is represented by two main subtypes of uveal (UM) and conjunctival (CM) melanoma with distinct clinical (frequency, localization, histology) and genomic features.
N. N. Mazurenko +7 more
doaj +1 more source
Molecular testing approaches in thyroid cancer diagnosis
Journal of Biochemical and Clinical Genetics, 2020 Thyroid cancer (TC) is the most common endocrine malignancy worldwide, with an annual incidence of around 300,000 cases. In recent decades, the incidence of TC in many countries, including Saudi Arabia, has increased significantly.
Abdul-Mohsen Gaeth AlHejaily +1 more
doaj +1 more source
Cancer Biology & Medicine, 2022 Objective: PD-L1 and PD-L2 expression levels determine immune evasion and the therapeutic efficacy of immune checkpoint blockade. The factors that drive inducible PD-L1 expression have been extensively studied, but mechanisms that result in constitutive ...
Panpan Ma +12 more
doaj +1 more source
In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms [PDF]
, 2018 Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo
Aplin, Andrew E. +14 more
core +1 more source
International Journal of General Medicine, 2023 Yeqian Lai,1,2 Yihua Gu,1,2 Ming Yu,1,2 Jiaqin Deng1,2 1Department of Thyroid Surgery, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Guangdong Provincial Key Laboratory of Precision Medicine and ...
Lai Y, Gu Y, Yu M, Deng J
doaj
Molecular features and genetic markers of gastrointestinal stromal tumors
Успехи молекулярной онкологии, 2015 Gastrointestinal stromal tumors (GISTs) are the most spread mesenchymal tumors located within the gastrointestinal tract that have particular clinico-morphological, immunohistochemical and molecular characteristics.
N. N. Mazurenko, I. МЮ Tsyganova
doaj +1 more source
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]
, 2018 Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John +8 more
core +1 more source